Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04861207 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes

Study acronym: CLARA
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Jan 31, 2025 to Dec 31, 2027v3 Show 4 more changesShow less
    • Start date changed from estimate of Jun 30, 2021 to Oct 7, 2021
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Site contact updated
    • Eligibility criteria shortened, about 1 word
  2. Secondary endpoints revised (6)v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A single center, prospective, one arm clinical study to assess the tolerance and effectiveness of total body irradiation and cladribine in adult patients diagnosed with AML( acute myeloid leukemia) and myelodysplastic syndromes.
Trial Details
NCT Number NCT04861207
Lead Sponsor Maria Sklodowska-Curie National Research Institute of Oncology
Collaborators: KCRI
Conditions
(from sponsor)		 Acute Myeloid Leukemia Myelodysplastic Syndromes
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov